Clinical Commander

Back to dossier
cardio.cardiac-tamponade.malignant.v1PRODUCTION
cardio.cardiac-tamponade.malignant.v1

Cardiac tamponade — malignant pericardial effusion

cardiologyacuteadult
Hard-required inputs
0 / 8
Care setting:

Encounter flow

9/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Malignant tamponade — drainage is bridge; surgical window typically required for durability given >50% 90-day recurrence post-pericardiocentesis-alone (El Haddad PMID 26515995; ESC 2015 §Neoplastic)

Inputs
1
Actions
0
Advance rule
Set
Advance when

cancer-context tamponade physiology suspected

Patient inputs (9)

Age modifies cancer-type distribution and surgical candidacy (Khandaker Mayo Clin Proc 2010 PMID 20656240)

Compensatory tachycardia in tamponade physiology (ESC 2015)

Lung/breast = 55% of malignant pericardial effusions; histology drives intrapericardial cytotoxic choice (Lestuzzi Heart 2010; Maisch ESC 2013)

On active chemo / immunotherapy / radiation? — affects bleeding risk + drug interactions (NCCN palliative 2024)

Definitive bedside dx — chamber collapse, IVC, swinging heart (ESC 2015 Class I)

Thrombocytopenia from chemo/marrow infiltration drives bleeding risk during drainage (NCCN 2024)

Coagulopathy in advanced cancer / liver mets (NCCN 2024)

Hypotension is part of Beck triad; pulsus paradoxus measurement (Spodick Circulation 2003)

Recurrence post-drainage drives pericardial window decision (El Haddad PMID 26515995)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningintrapericardial_bleeding_post_cytotoxic_instillation
    New bleeding into pericardial space post-cisplatin/bleomycin/mitomycin instillation OR baseline thrombocytopenia <30k → hemorrhagic effusion (Maisch ESC 2013)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningconcurrent_neutropenic_fever_during_drainage
    Neutropenic fever (ANC <500 + T ≥38.3) coinciding with malignant tamponade — purulent pericarditis must be excluded
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererapid_recurrence_within_30d_post_pericardiocentesis
    Re-accumulation within 30 days of initial pericardiocentesis in malignant etiology — predictor of >50% 90-day recurrence (El Haddad JACC 2015 PMID 26515995)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepericardial_decompression_syndrome
    Acute LV dilation + LV dysfunction within 24h of large-volume (>1000 mL) pericardial drainage in chronic effusion (Pratt JACC 2019; reported in malignant effusions where chronic large effusions accumulate slowly)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremalignant_etiology_with_advanced_cancer_and_poor_performance_status
    Tamponade in patient with progressive metastatic cancer + ECOG ≥3 + life expectancy <3 mo — drainage decision is goals-of-care-driven (NCCN palliative 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Malignant pericardial effusion — drainage with high-recurrence durability strategy (ESC 2015 §Neoplastic; Lestuzzi Heart 2010)
axis: malignant_pericardial_drainage_and_durability
Selected axis "Malignant pericardial effusion — drainage with high-recurrence durability strategy (ESC 2015 §Neoplastic; Lestuzzi Heart 2010)" by default fallback (first axis)
  • normal saline
    first line
    isotonic_crystalloid
    500-1000 mL bolus • IV • rapid bolus then reassess
    triggers: hypotension_pre_drainage
    Increase preload as bridge to drainage (ESC 2015)
    rxcui 9863
  • norepinephrine
    rescue
    vasopressor
    0.05-0.1 µg/kg/min titrate to MAP ≥65 • IV • continuous
    triggers: SBP_lt_85_despite_fluids
    Bridge only — does not address obstruction (Roy JAMA 2007)
    rxcui 7512
  • cisplatin
    add on
    platinum_alkylating_agent
    10-30 mg intrapericardial single dose post-drainage • intrapericardial • single dose; may repeat in 7d if persistent recurrence
    triggers: lung_cancer_etiology, refractory_recurrence_post_window
    Maisch ESC 2013 + Patel Eur J Cancer 2013 PMID 23290429 — durable response in lung ca; AVOID if eGFR <30; pre-medicate with antiemetics
    rxcui 2555
  • bleomycin
    add on
    antineoplastic_glycopeptide
    15-60 mg intrapericardial • intrapericardial • single dose; may repeat
    triggers: breast_or_lymphoma_etiology, cisplatin_contraindicated
    Lestuzzi Heart 2010 — alternative cytotoxic for non-lung primaries; pulmonary toxicity risk if systemic
    rxcui 1621
  • mitomycin
    add on
    antineoplastic_alkylating
    5-10 mg intrapericardial • intrapericardial • single dose
    triggers: gi_or_genitourinary_cancer_etiology
    Maisch ESC 2013 — third-line cytotoxic option for refractory recurrence
    rxcui 632

outpatient playbook — drug actions (3)

  1. 1. continue systemic anti-cancer therapy
    per oncology regimen • per regimen • per regimen
    trigger: Disease-active
    Primary etiology-directed therapy (NCCN 2024)
  2. 2. analgesia regimen titration
    rxcui 161
    acetaminophen + opioid per WHO ladder • PO • as needed
    trigger: Cancer pain
    NCCN palliative 2024
  3. 3. intrapericardial cytotoxic re-instillation referral
    rxcui 2555
    cisplatin 10-30 mg or bleomycin 15-60 mg • intrapericardial via re-drainage • per recurrence event
    trigger: ≥2 recurrences despite window or window-not-feasible patient with refractory recurrence
    Maisch ESC 2013 — selected refractory cases

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Known active malignancy (lung, breast, lymphoma, leukemia, melanoma, GI) presenting with new dyspnea + hypotension + JVD (Lestuzzi Heart 2010; Ristić EHJ 2014); Echo: pericardial effusion (often large >2 cm) + RV diastolic collapse / IVC plethora in cancer patient (ESC 2015 §Neoplastic Pericardial Disease); Incidental pericardial effusion on staging CT in oncology patient — outpatient triage to echo + tamponade screen (Imazio JACC 2020 PMID 32919577).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiac tamponade — malignant pericardial effusion** (cardio.cardiac-tamponade.malignant.v1).
Phenotype framing: Confirm malignant etiology via fluid: cytology + flow cytometry + cell block (sensitivity 70-90% pooled; Lestuzzi Heart 2010); consider immunohistochemistry for primary site identification if cancer of unknown primary
Scope: Malignant tamponade — drainage is bridge; surgical window typically required for durability given >50% 90-day recurrence post-pericardiocentesis-alone (El Haddad PMID 26515995; ESC 2015 §Neoplastic)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Malignant pericardial effusion — drainage with high-recurrence durability strategy (ESC 2015 §Neoplastic; Lestuzzi Heart 2010)**.
1. normal saline 500-1000 mL bolus IV rapid bolus then reassess (isotonic_crystalloid, first line) — Increase preload as bridge to drainage (ESC 2015)
2. norepinephrine 0.05-0.1 µg/kg/min titrate to MAP ≥65 IV continuous (vasopressor, rescue) — Bridge only — does not address obstruction (Roy JAMA 2007)
3. cisplatin 10-30 mg intrapericardial single dose post-drainage intrapericardial single dose; may repeat in 7d if persistent recurrence (platinum_alkylating_agent, add on) — Maisch ESC 2013 + Patel Eur J Cancer 2013 PMID 23290429 — durable response in lung ca; AVOID if eGFR <30; pre-medicate with antiemetics
4. bleomycin 15-60 mg intrapericardial intrapericardial single dose; may repeat (antineoplastic_glycopeptide, add on) — Lestuzzi Heart 2010 — alternative cytotoxic for non-lung primaries; pulmonary toxicity risk if systemic
5. mitomycin 5-10 mg intrapericardial intrapericardial single dose (antineoplastic_alkylating, add on) — Maisch ESC 2013 — third-line cytotoxic option for refractory recurrence

Setting playbook (outpatient) — Long-term surveillance for malignant pericardial recurrence + multidisciplinary disease-status monitoring + goals-of-care alignment (Lestuzzi Heart 2010; NCCN palliative 2024)
6. continue systemic anti-cancer therapy per oncology regimen per regimen per regimen — Disease-active (Primary etiology-directed therapy (NCCN 2024))
7. analgesia regimen titration acetaminophen + opioid per WHO ladder PO as needed — Cancer pain (NCCN palliative 2024)
8. intrapericardial cytotoxic re-instillation referral cisplatin 10-30 mg or bleomycin 15-60 mg intrapericardial via re-drainage per recurrence event — ≥2 recurrences despite window or window-not-feasible patient with refractory recurrence (Maisch ESC 2013 — selected refractory cases)

Non-pharmacologic actions:
- Multidisciplinary clinic visits q4-12 wk based on disease activity
- Activity per performance status + cardiac rehab if appropriate
- Advance directive renewal annually
- Hospice transition when goals-of-care shift to comfort

AVOID / contraindication checks:
- Positive_pressure_ventilation_AVOID_pre_drain_drops_preload (ESC 2015)
- Colchicine_NOT_recommended_malignant_no_benefit_GI_toxicity_in_chemo_pts (ESC 2015 §Neoplastic)
- NSAIDs_AVOID_thrombocytopenia_or_active_chemo_with_platelet_lt_75k (NCCN 2024)
- Cisplatin_AVOID_egfr_lt_30 (drug label)
- Bleomycin_AVOID_prior_pulmonary_toxicity_or_total_lifetime_dose_gt_400u (drug label)
- Platelet_threshold_50k_for_drainage_75k_for_window (NCCN 2024 procedural)

Monitoring

Regimen monitoring:
- continuous ECG during drainage (ESC 2015)
- art line BP pre and post (Adler 2015)
- echo post drain immediate then q12-24h x 72h then weekly outpatient (recurrence rate >50% at 90d for malignant per El Haddad PMID 26515995)
- fluid analysis cytology flow cytometry cell block essential (Lestuzzi Heart 2010 — sensitivity 70-90% pooled)
- oncology disease status update q4-8wk (NCCN palliative 2024)
- platelet count q24h during drainage (NCCN 2024)

Setting (outpatient) monitoring:
- Echo q3 mo × 1 yr
- CBC + tumor markers per oncology
- ESAS symptom log monthly

Monitoring phase: Re-accumulation surveillance (echo q12-24h initially then weekly outpatient); fluid analysis (cytology, flow cytometry, cell block, cell count, glucose, LDH, ADA); CRP trend; oncologic disease-status updates (Imazio JACC 2020)

Disposition

Current setting: outpatient — Long-term surveillance for malignant pericardial recurrence + multidisciplinary disease-status monitoring + goals-of-care alignment (Lestuzzi Heart 2010; NCCN palliative 2024)

Disposition criteria:
- Long-term continuation under multidisciplinary team; cross-link to cardio.cardiac-tamponade.core.v1 for acute recurrence pathway

Escalation triggers (move to higher acuity):
- Recurrent tamponade → re-drainage + escalate to intrapericardial cytotoxic or repeat window per multidisciplinary review
- Disease progression → systemic therapy intensification or hospice transition
- Refractory symptoms → palliative care intensification

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] New bleeding into pericardial space post-cisplatin/bleomycin/mitomycin instillation OR baseline thrombocytopenia <30k → hemorrhagic effusion (Maisch ESC 2013)
- [LIFE_THREATENING] Neutropenic fever (ANC <500 + T ≥38.3) coinciding with malignant tamponade — purulent pericarditis must be excluded
- [SEVERE] Re-accumulation within 30 days of initial pericardiocentesis in malignant etiology — predictor of >50% 90-day recurrence (El Haddad JACC 2015 PMID 26515995)

Citations

- 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Neoplastic Pericardial Disease — remains current as of 2026-05-14. Lestuzzi Heart 2010 + Maisch ESC 2013 + NCCN palliative care 2024 anchor malignant-specific drainage durability + intrapericardial cytotoxic + multidisciplinary frameworks. [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 17456823) [PMID:17456823](https://pubmed.ncbi.nlm.nih.gov/17456823/)
- Cited evidence (PMID 20656240) [PMID:20656240](https://pubmed.ncbi.nlm.nih.gov/20656240/)
- Cited evidence (PMID 26515995) [PMID:26515995](https://pubmed.ncbi.nlm.nih.gov/26515995/)
- Cited evidence (PMID 32919577) [PMID:32919577](https://pubmed.ncbi.nlm.nih.gov/32919577/)

Last reconciled with current guidelines: 2026-05-14.
References
  • 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Neoplastic Pericardial Disease — remains current as of 2026-05-14. Lestuzzi Heart 2010 + Maisch ESC 2013 + NCCN palliative care 2024 anchor malignant-specific drainage durability + intrapericardial cytotoxic + multidisciplinary frameworks. — PMID:26320112
  • Cited evidence (PMID 17456823) — PMID:17456823
  • Cited evidence (PMID 20656240) — PMID:20656240
  • Cited evidence (PMID 26515995) — PMID:26515995
  • Cited evidence (PMID 32919577) — PMID:32919577